Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Rowland

Showing results (141-150 of 184) with videos related to

Pageof 19
Sort By:
Atherosclerosis|October 17, 2017
Opposing effects of rheumatoid arthritis and low dose prednisolone on arginine metabolomicsAnjana Radhakutty, Brenda L Mangelsdorf, Sophie M Drake, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|March 25, 2015
Characterization of the comparative drug binding to intra- (liver fatty acid binding protein) and extra- (human serum albumin) cellular proteinsAndrew Rowland, David Hallifax, Matthew R Nussio, et al.
Journal of Clinical Pharmacology|January 12, 2019
Use of Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Axitinib Exposure: A Fresh Approach to Precision Dosing in OncologyMichael J Sorich, Fayzah Mutlib, Madelé van Dyk, et al.
Critical Reviews in Oncology/Hematology|February 29, 2020
A literature review of treatment-specific clinical prediction models in patients with breast cancerNatansh D Modi, Michael J Sorich, Andrew Rowland, et al.
Journal of the International Society of Sports Nutrition|February 13, 2026
A comprehensive review of the physiology and evidence base to guide the use of ergogenic and medical supplements for enhanced cycling performanceAndrew Rowland, Sophie Edwards, Gorka Prieto-Bellver, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2024
Clinical Study Report and Individual Participant Data Transparency for US Food and Drug Administration-Approved Anticancer Drugs: A Call for Systematic Data AvailabilityNatansh D Modi, Sandra M Swain, Marc Buyse, et al.
Clinical and Translational Science|December 18, 2023
Study of the ketohexokinase inhibitor PF-06835919 as a clinical cytochrome P450 3A inducer: Integrated use of oral midazolam and liquid biopsyRuolun Qiu, Kari Fonseca, Arthur Bergman, et al.
Breast (Edinburgh, Scotland)|April 27, 2021
Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclibNatansh D Modi, Ahmad Y Abuhelwa, Sarah Badaoui, et al.
Journal of Extracellular Vesicles|May 28, 2026
Extracellular Vesicles as Enabling Biomarkers for New Approach Methodologies to Support the US Food and Drug Administration Modernization Act 3.0Andrew Rowland, Carl Kirkpatrick, A David Rodrigues, et al.
Biochemical Pharmacology|January 10, 2017
Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemiaJohn O Miners, Nuy Chau, Andrew Rowland, et al.
Pageof 19

Showing results (141-150 of 184) with videos related to

Sort By:
Pageof 19
Atherosclerosis|October 17, 2017
Opposing effects of rheumatoid arthritis and low dose prednisolone on arginine metabolomicsAnjana Radhakutty, Brenda L Mangelsdorf, Sophie M Drake, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|March 25, 2015
Characterization of the comparative drug binding to intra- (liver fatty acid binding protein) and extra- (human serum albumin) cellular proteinsAndrew Rowland, David Hallifax, Matthew R Nussio, et al.
Journal of Clinical Pharmacology|January 12, 2019
Use of Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Axitinib Exposure: A Fresh Approach to Precision Dosing in OncologyMichael J Sorich, Fayzah Mutlib, Madelé van Dyk, et al.
Critical Reviews in Oncology/Hematology|February 29, 2020
A literature review of treatment-specific clinical prediction models in patients with breast cancerNatansh D Modi, Michael J Sorich, Andrew Rowland, et al.
Journal of the International Society of Sports Nutrition|February 13, 2026
A comprehensive review of the physiology and evidence base to guide the use of ergogenic and medical supplements for enhanced cycling performanceAndrew Rowland, Sophie Edwards, Gorka Prieto-Bellver, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2024
Clinical Study Report and Individual Participant Data Transparency for US Food and Drug Administration-Approved Anticancer Drugs: A Call for Systematic Data AvailabilityNatansh D Modi, Sandra M Swain, Marc Buyse, et al.
Clinical and Translational Science|December 18, 2023
Study of the ketohexokinase inhibitor PF-06835919 as a clinical cytochrome P450 3A inducer: Integrated use of oral midazolam and liquid biopsyRuolun Qiu, Kari Fonseca, Arthur Bergman, et al.
Breast (Edinburgh, Scotland)|April 27, 2021
Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclibNatansh D Modi, Ahmad Y Abuhelwa, Sarah Badaoui, et al.
Journal of Extracellular Vesicles|May 28, 2026
Extracellular Vesicles as Enabling Biomarkers for New Approach Methodologies to Support the US Food and Drug Administration Modernization Act 3.0Andrew Rowland, Carl Kirkpatrick, A David Rodrigues, et al.
Biochemical Pharmacology|January 10, 2017
Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemiaJohn O Miners, Nuy Chau, Andrew Rowland, et al.
Pageof 19